Healthcare Sector Prepares for JNJ Earnings, Biotech Trial Updates, and FDA Decisions
The healthcare and biotechnology sectors are entering an event-filled week featured by third-quarter financial results from Johnson & Johnson (JNJ), key regulatory decision deadlines from the U.S. Food and Drug Administration, and multiple clinical trial updates from drug developers.
Johnson & Johnson (JNJ) is scheduled to post quarterly earnings on Tuesday, with consensus estimates pointing to revenue of $25.38 billion and GAAP earnings per share of $2.07. Meanwhile, biotech investors are tracking upcoming regulatory targets, including an FDA decision deadline for Roche (RHHBY) on its thyroid eye disease therapy Enspryng, and an October 17 target date for Viatris (VTRS) and Opus Genetics (IRD) regarding phentolamine eye drops for presbyopia.
Clinical presentations will also headline the week. Cytokinetics, Incorporated (CYTK) will showcase late-breaking study data for Aficamten ahead of a planned supplemental new drug application in the fourth quarter. Arrowhead Pharmaceuticals, Inc. (ARWR) plans to share interim early-stage data for its Alzheimer's disease candidate ARO-MAPT on Wednesday, while Verastem Oncology (VSTM) presents initial efficacy results for its KRAS G12D cancer treatment.
Key points
- Johnson & Johnson (JNJ) reports Q3 results on Tuesday with revenue expected at $25.38 billion.
- Roche (RHHBY) awaits an FDA decision on Enspryng for thyroid eye disease by Thursday.
- Viatris (VTRS) and Opus Genetics (IRD) face an October 17 FDA decision date for presbyopia eye drops.
- Arrowhead Pharmaceuticals, Inc. (ARWR) presents interim Phase 1 data for Alzheimer's candidate ARO-MAPT on Wednesday.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When does Johnson & Johnson report Q3 earnings?
Johnson & Johnson is scheduled to report its third-quarter financial results on Tuesday.
What are the key FDA decision dates for eye therapies this week?
Roche awaits an FDA decision on Enspryng for thyroid eye disease by Thursday, while Viatris and Opus Genetics face an October 17 FDA target date for phentolamine eye drops to treat presbyopia.
What data is Arrowhead Pharmaceuticals presenting this week?
Arrowhead Pharmaceuticals will present interim early-stage clinical trial results for ARO-MAPT, its investigational treatment for Alzheimer's disease and related tau disorders, on Wednesday.